Free Cardiology CME 2017‑2018 | CMEList.com

 


PCSK9 Inhibitors and CV Risk Reduction: Understanding the Implications
Free Cardiology CME Free Diiabetes CME Live online April 11, 2017 (Session 1) and May 23, 2017 (Session 2) and available on demand through October 11, 2017 (Session 1) and November 23, 2017 (Session 2).
Posted by...Bernard Sklar, MD.
Free Cardiology CME Credit hours..1.0.
CME Credits Awarded by....National Lipid Association.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management and CV disease risk reduction.
Educational material updated...May 23, 2017.
Expiration of CME credit...November 23, 2017.
PCSK9 Inhibitors and CV Risk Reduction: Understanding the Implications is presented in two sessions:
• Session 1: The Emerging Role of PCSK9 Inhibitors and CV Risk Reduction
• Session 2: CVD and PCSK9 Inhibitors: Analyzing the Outcome Studies and Understanding Their Implications 
After viewing PCSK9 Inhibitors and CV Risk Reduction: Understanding the Implications, you will be better able to :
• Identify the need for effective therapies for patients with familial hypercholesterolemia
• Assess the efficacy and safety data for recent trials that examined the cardiovascular impact of PCSK9 inhibitors
• Evaluate patient groups in which treatment beyond statins may be needed to decrease lipid-related CV risk

Cardiovascular Disease, Diabetes, and Diabetes Treatments: Understanding the Interrelationships
Free Cardiology CME Free Diiabetes CME Live online March 1, 2017, (Sessions 1 and 2), and March 29, 2017 (Session 3), and available on demand through September 29 2017.
Posted by...Bernard Sklar, MD.
Free Cardiovascular and Diabetes CME Credit hours...3.0.
CME Credits Awarded by....University of Cincinnati.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for primary care clinicians, diabetes specialists, cardiologists, as well as other health care providers who provide front-line glycemic management for type 2 diabetes (T2DM) and its comorbidities.
Educational material updated...March 29, 2017.
Expiration of CME credit...September 29 2017.
Financial Support...Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC, and Novo Nordisk Inc.
This activity consists of three sessions, each of which should take approximately 1 hour to complete.
At the conclusion of Cardiovascular Disease, Diabetes, and Diabetes Treatments, you will be able to:
• Discuss the etiologic and pathophysiologic interconnections among the components of the cardiometabolic syndrome and the development of cardiovascular disease
• Identify pharmacological actions of antidiabetes medications that could potentially impact cardiovascular outcomes
• Describe the rationale for studying the cardiovascular impact of antidiabetes medications
• Compare and contrast antidiabetes pharmacotherapies which can optimize glycemic control and minimize adverse effects on cardiovascular risk and/or disease
• Discuss the efficacy and safety data for recent trials that examined the cardiovascular impact of antidiabetes medications
• Delineate critical assessments of recent cardiovascular outcomes trials for antidiabetes medications with regard to their evidence-based clinical implications

Hyperkalemia: Causes, Consequences, and Treatment
Free Hyperkalemia CME Posted by...Bernard Sklar, MD.
Free CME Credit Hours...0.75.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Video Lectures.
Target Audience...Nephrologists, endocrinologists, cardiologists, internal medicine physicians, primary care physicians and other health care professionals involved in the treatment of patients with hyperkalemia.
Educational material last updated...December 14, 2016.
CME Credit Expires...December 13, 2017.
Financial Support...Relypsa, Inc.
Hyperkalemia: Causes, Consequences, and Treatment consists of three brief video presentations on hyperkalemia.
Upon successful completion of Hyperkalemia: Causes, Consequences, and Treatment, you should be better able to:
• Describe the pathophysiology of hyperkalemia, etiologic factors associated with its presentation, and its potential effect on multiple organ systems.
• Review the symptoms that commonly present in patients with hyperkalemia to assist in determining the appropriate diagnostic follow-up.
Differentiate among the new and emerging agents for hyperkalemia for improved treatment selection.
• Apply the efficacy and safety data of conventional therapy and emerging treatments when selecting therapy for hyperkalemia in patients with chronic kidney disease or end-stage renal disease and chronic heart failure.
• Select the appropriate treatment for patients with diabetes and hyperkalemia.

ScientiaCME Cardiology/Pulmonology Free Cardiology CME ScientiaCME Cardiology/Pulmonology
Posted by...Bernard Sklar, MD.
CME Credit Hours...2.0.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Slide-Video Lectures.
Target Audience...CARDIOLOGY, CHEST MEDICINE, FAMILY MEDICINE, INTERNAL MEDICINE.
CME Credit Expires...Two years after release.
Financial Support...Various commercial supporters.

ScientiaCME Treatment strategies in Gaucher disease Free Gaucher Disease CME
CME Credit Hours...1.25.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Slide-Video Lectures.
Target Audience...Cardiology, genetic disorders, hematology, oncology, orthopedics, gastroenterology, neurology and pediatrics.
Educational material updated....February 12, 2017.
Expiration of CME credit...February 12, 2019.
Financial Support...Shire.
At the conclusion of By the end of Treatment strategies in Gaucher disease, you will be able to:
• Describe the importance of appropriate GD (Gaucher Disease) diagnosis and treatment (use • for bullets)
• Determine the likelihood of GD using with established diagnosis methods, given a patient case
• Describe present therapies for the treatment of GD and the literature supporting their use
• Design a medical plan to treat a patient with GD, taking into account presently available therapies